Shopping Cart
- Remove All
- Your shopping cart is currently empty
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC), with potential to treat tumor-induced bone disease (TIBD).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $293 | In Stock | |
2 mg | $436 | In Stock | |
5 mg | $722 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,520 | In Stock | |
50 mg | $1,980 | In Stock |
Description | MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC), with potential to treat tumor-induced bone disease (TIBD). |
In vitro | In human multiple myeloma cell lines (KAS-6/1, DP-6, KP-6), MBC-11 (0.1-100 µM) significantly inhibited multiple myeloma cell proliferation in each cell line at the majority of tested concentrations[1]. |
In vivo | In approximately four-week-old female Balb/c mice with a breast tumor model, MBC-11 (0.04, 0.4, or 4.0 μg/day; subcutaneous injection daily from day 7 to day 21) at a dose of 0.04 μg/day had a lower incidence of bone metastases compared to those treated with PBS or 0.04 μg/day zoledronate[1]. |
Molecular Weight | 511.21 |
Formula | C11H20N3O14P3 |
Cas No. | 332863-86-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.